The aim was straightforward and highly-laudable: find methods for supplying use of cheaper, generic versions of patented drugs in developing countries to combat public health crises caused by Aids/AIDS, t . b, malaria or any other epidemics.

Yet, nearly ten years after global agencies started to create developing countries to purchase or manufacture